LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked ...

Outlook Therapeutics, Inc. has announced a key development in the treatment of wet age-related macular degeneration (wet AMD) with the National Institute for Health and Care Excellence (NICE) ...

VLTR-559 demonstrates sustained anti-VEGF activity and favorable safety at target clinical dosefor treatment of wetage-related macular ...

A single injection of the tyrosine kinase inhibitor hydrogel has demonstrated superiority to aflibercept 2 mg in maintaining visual acuity and providing higher rescue-free rates through 1 year in ...

Clearside Biomedical, Inc. announced on March 20, 2025, that it presented findings on its lead clinical program, CLS-AX, a suprachoroidal injectable suspension of axitinib, at the 2025 Wet AMD & ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A phase 2a study of 38 patients showed promising results ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. There are a variety of ways that I would ...

When ophthalmologist Richard B. Rosen, MD, of New York Eye and Ear Infirmary of Mount Sinai in New York City, started his career more than 30 years ago, advanced age-related macular degeneration (AMD) ...

—A new analysis took a 2-prong approach to assessing risk factors for wet age-related macular degeneration: a systematic review of the literature, coupled with a study of decades’ worth of data from ...

The use of GLP-1 receptor agonists was associated with a substantially lower long-term risk for dry age-related macular degeneration (AMD) than the use of other weight-loss medications in adults with ...